Literature DB >> 30853409

Bites by Tomodon dorsatus (serpentes, dipsadidae): Clinical and epidemiological study of 86 cases.

Carlos Roberto de Medeiros1, Solange Nogueira de Souza2, Milene Cirino da Silva2, Janaina de Souza Ventura2, Roberta de Oliveira Piorelli2, Giuseppe Puorto3.   

Abstract

A total of 86 proven cases of Tomodon dorsatus bites admitted to Hospital Vital Brazil (HVB) of Butantan Institute, in São Paulo, Brazil, between 1945 and 2018, were retrospectively analyzed. The cases included were those in which the snake was brought to HVB and was correctly identified. Of the 86 cases of snake bites, it was possible to describe the sex of the snake in 52 cases; 31 (59.6%) snakes were male. Only 52 snakes out of 86 could be studied because of their preservation status. The length of snakes (snout-vent length) ranged from 180 to 770 mm. Of the 86 snakes, 72 could be distinguished as adults (n = 63, 87.5%) or juveniles (n = 9, 12.5%). Most bites occurred in the spring and summer seasons (n = 57, 66.3%) and during warmer periods of the day (n = 61, 72.6%), between 9 a.m. and 3 p.m. The mean (±standard deviation) age of the victims was 26.9 ± 17.2 years, and 60 (69.8%) were men. Approximately 90% of the patients sought medical care within 6 h after the bite. Both upper (n = 45, 52.3%) and lower (n = 37, 43.0%) limbs were the most frequently bitten, particularly the feet and hands (n = 54, 62.8%). The local clinical manifestations were pain (n = 55, 64.0%), transitory bleeding (n = 23, 26.7%), erythema (n = 22, 25.6%), edema (n = 14, 16.3%), paresthesia (n = 9, 10.5%), and ecchymosis (n = 3, 3.5%). Only 10 (11.6%) patients reported non-specific systemic symptoms characterized by transient dizziness or mild headache, and 21 (24.4%) patients showed no evidence of envenomation. A 20 min whole blood clotting test was performed in 31 (36.0%) patients on admission and all of them had coagulable blood. Supportive treatment was offered to 38 (44.2%) patients, namely, antiseptic (n = 20, 23.3%), antihistamines (n = 12, 14.0%), and analgesics (n = 9, 10.5%). Four (4.7%) patients were inappropriately treated with Bothrops antivenom before their admission to HVB. No sequelae or relevant complications were observed in patients, and the prognosis was benign. Therefore, although T. dorsatus bites can cause mild local symptomatology, it is important that health professionals know how to make the correct diagnosis to avoid unnecessary use of antivenom.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Dipsadidae: non-front-fanged colubroid; Envenomation; Snakebite; Tomodon dorsatus

Mesh:

Substances:

Year:  2019        PMID: 30853409     DOI: 10.1016/j.toxicon.2019.03.005

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  5 in total

1.  Identifying the snake: First scoping review on practices of communities and healthcare providers confronted with snakebite across the world.

Authors:  Isabelle Bolon; Andrew M Durso; Sara Botero Mesa; Nicolas Ray; Gabriel Alcoba; François Chappuis; Rafael Ruiz de Castañeda
Journal:  PLoS One       Date:  2020-03-05       Impact factor: 3.240

Review 2.  Investigating Toxin Diversity and Abundance in Snake Venom Proteomes.

Authors:  Theo Tasoulis; Tara L Pukala; Geoffrey K Isbister
Journal:  Front Pharmacol       Date:  2022-01-14       Impact factor: 5.810

Review 3.  Review of the Mechanisms of Snake Venom Induced Pain: It's All about Location, Location, Location.

Authors:  Vance G Nielsen; Michael T Wagner
Journal:  Int J Mol Sci       Date:  2022-02-15       Impact factor: 5.923

4.  A Retrospective Evaluation of Snake Envenomation in Dogs in South Korea (2004-2021).

Authors:  Jeong-Min Lee; Joong-Hyun Song; Kun-Ho Song
Journal:  Toxins (Basel)       Date:  2022-08-18       Impact factor: 5.075

Review 5.  Bedside Coagulation Tests in Diagnosing Venom-Induced Consumption Coagulopathy in Snakebite.

Authors:  Supun Wedasingha; Geoffrey Isbister; Anjana Silva
Journal:  Toxins (Basel)       Date:  2020-09-10       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.